NCT00834678View on ClinicalTrials.gov

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

August 31, 2013

Study Completion Date

September 30, 2014

Conditions
Breast Cancer
Interventions
DRUG

bendamustine

100 or 120 mg/m2 IV on days 1 and 2

DRUG

erlotinib

100 or 150 mg po on days 5 - 21 of each 28 day cycle

DRUG

Maintenance erlotinib

150 mg po daily (days 1 - 28 of 28 day cycle)

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Genentech, Inc.

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER